Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
New and experimental hepatitis C treatment
Vertex Joins Glaxo, J&J in Testing Hepatitis C Combos

Vertex Pharmaceuticals Inc. (VRTX), maker of the hepatitis C drug Incivek, said it agreed to test one of its experimental therapies for the disease with other drugs from Johnson & Johnson (JNJ) and GlaxoSmithKline Plc. (GSK).

Published
01 November 2012
From
Bloomberg BusinessWeek
New and experimental hepatitis C treatment
BioCryst drops hep C drug on safety issues

BioCryst Pharmaceuticals Inc said it would withdraw an application to test its experimental hepatitis C drug in humans after the U.S. Food and Drug Administration expressed concern about its safety.

Published
31 October 2012
From
Reuters
New and experimental hepatitis C treatment
Will Dropping Interferon Be the Magic Bullet for Reducing HCV Mortality?

Let’s start with the basic premise that most individuals with chronic hepatitis C would like to be cured of this potentially life-threatening infection. If this premise is true, why then has the large majority of HCV-infected patients in the United States not been treated with previous and current standard therapies?

Published
26 October 2012
From
Clinical Care Options (requires registration)
Access to medicines and treatment
Pakistan: PAC forms panel to relaunch cheaper hepatitis medication

The Public Accounts Committee (PAC) has formed a committee to assess why low-cost, locally manufactured interferon, used to treat hepatitis C, was not marketed in the country. Dr Sheikh Riazuddin, the former director of the Centre of Excellence in Molecular Biology (CEMB), had developed the low-cost interferon injection and proposed to sell it for Rs70 per injection. The interferon injection that passed its test phase would cost significantly less than the imported version which is Rs900 per injection.

Published
24 October 2012
From
Express Tribune
New and experimental hepatitis C treatment
Bristol-Myers has brought in Insight Public Affairs - Prepares to launch first hepatitis C drugs in UK

Bristol-Myers Squibb has brought in Insight Public Affairs as it prepares to launch its first hepatitis C drugs in the UK. The three-year retained brief is believed to include public affairs and stakeholder management to pave the way for the drugs’ entry into the market.The agency has also been briefed to move hepatitis up the political agenda, while providing insight into the UK policy environment.

Published
24 October 2012
From
PR Week
New and experimental hepatitis C treatment
Setbacks in HCV Drug Development Highlight Uncertainties in Treat or Wait Decisions

Following recent problems with emerging drugs for HCV, I am reminded of the difficulties of turning chemicals into drugs and the importance of waiting until the development cycle is complete before claiming success.I first sensed trouble in April 2012 when it was announced that trials of alisporivir were being suspended.

Published
23 October 2012
From
Clinical Care Options (requires registration)
Pharmaceutical industry
Vertex Draws Collaboration Interest For Hepatitis C Combo

Vertex Pharmaceuticals Inc. (VRTX), maker of the hepatitis C drug Incivek, has received interest from other companies to collaborate on tests of one of its experimental medicines for the liver disease, Chief Executive Officer Jeffrey Leiden said.

Published
19 October 2012
From
Bloomberg BusinessWeek
Pharmaceutical industry
BioCryst scoops up early-stage Hep C drugs in $101M Presidio acquisition

BioCryst Pharmaceuticals ($BCRX) has put together a deal to acquire a small biotech in San Francisco in an all-stock deal valued at $101 million. The Durham, NC-based BioCryst will gain some early-stage hepatitis C drug components as it absorbs Presidio Pharmaceuticals into the company, which will seek a new identity under a different name.

Published
18 October 2012
From
FierceBiotech
New and experimental hepatitis C treatment
A New And Interesting Addition To The Hep C Clinical Pipeline

The race towards an interferon-free hepatitis C treatment continues to heat up, with a newcomer to the clinical pipeline - BioLine Rx's (BLRX) BL-8020.

Published
18 October 2012
From
Seeking Alpha
New and experimental hepatitis C treatment
MSD bemoans slow uptake for hep C drugs

MSD has revealed new data that it says shows new hepatitis C drugs are seeing slow uptake in the UK. Referencing a 2012 report by the UK’s Health Protection Agency, it says these new data - which looks at the prescribing of new oral treatments for chronic hepatitis C (genotype 1) in the UK - show that less than 1 in 100 (or 0.9%*) of eligible patients are receiving these drugs.

Published
17 October 2012
From
Pharma Times
← Prev1...34567...22Next →

Filter by country